Roche Bets $1.97B on Undisclosed Allosteric Targets: Platform Conviction Without Asset Validation

Heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF): Approximately 50% of symptomatic heart failure patients have HFpEF, yet characterisation and diagnosis criteria vary due to incomplete disease understanding, and unmet medical needs requiring new treatments remain. HFpEF carries considerable mortality risk and is associated with poor patient outcomes, frequent hospitalisations, and common comorbidities, with costs data scarce but economic burden increasing.

Non-albuminuric diabetic kidney disease (NA-DKD): This emerging phenotype — defined by progressive eGFR loss below 60 mL/min/1.73m² in the absence of albuminuria (UACR <30 mg/g) — has increasing prevalence but no established effective treatment. Patients with NA-DKD face elevated risks of death and heart failure hospitalisation compared with non-DKD diabetic patients, and only limited data support SGLT2 inhibitor use in this group, underscoring the need for dedicated clinical research.

CKD patients across the albuminuria spectrum: The EMPA-KIDNEY trial demonstrated that empagliflozin halved the chronic eGFR slope (from −2.75 to −1.37 mL/min/1.73m² per year; relative difference 50%, 95% CI 42–58), including among patients with little or no albuminuria — challenging guideline stratification that restricts SGLT2 inhibitor use based on albuminuria status alone.

Patients with peripheral artery disease (PAD) and diabetes: PAD patients were substantially underrepresented in major cardiovascular outcome trials of SGLT2 inhibitors and GLP-1 receptor agonists, leaving the benefit-risk profile in this population — including the amputation signal observed with canagliflozin — incompletely characterised.

Optimising drug class selection in high-risk type 2 diabetes: While both SGLT2 inhibitors and GLP-1 receptor agonists significantly reduce MACE versus placebo (HR 0.89, 95% CI 0.84–0.95 and HR 0.82, 95% CI 0.78–0.87, respectively), their secondary outcome profiles diverge markedly — SGLT2 inhibitors showing pronounced benefits for heart failure hospitalisation (HR 0.68) and composite renal outcomes (HR 0.69), and GLP-1 receptor agonists showing greater benefits for atherosclerotic events and weight loss. The optimal individualised treatment strategy based on predominant comorbidities remains an active unmet need.

Rare and monogenic kidney diseases such as Alport syndrome: Current therapies including renin-angiotensin system inhibitors leave many patients progressing to kidney failure at a young age. GLP-1 receptor agonists, with their anti-inflammatory, anti-fibrotic, and antioxidative mechanisms, are proposed as a potential therapeutic avenue, but Alport syndrome patients are absent from existing clinical trials.

Incretin receptor co- and tri-agonism (GLP-1R / GIPR / GCGR): Unimolecular dual- and triple-receptor agonists simultaneously activate GLP-1R, GIPR, and the glucagon receptor (GCGR), combining anorectic and insulinotropic activities with glucagon-mediated energy expenditure. Optimized triagonists have been shown to normalize body weight in diet-induced obese mice and enhance energy expenditure in a manner superior to GLP-1R mono-agonists and GLP-1R/GIPR co-agonists, with GcgR activation identified as the differentiating factor. Whether synergistic or antagonistic interactions arise from simultaneous stimulation of these G-protein signaling pathways remains under investigation.

Non-steroidal mineralocorticoid receptor antagonism (finerenone): Finerenone has emerged as a therapeutic option for patients with type 2 diabetes and chronic kidney disease, reducing albuminuria and providing cardiovascular and renal protection by reducing inflammation and fibrosis. Hyperkalemia remains an important adverse effect requiring routine monitoring.

Targeted anti-inflammatory immunotherapy for atherosclerosis: Pro-inflammatory cytokines — including IL-1β, IL-6, TNFα, and CCL2 — have been identified as therapeutic targets in atherosclerotic cardiovascular disease. Treatment with canakinumab, a monoclonal antibody targeting and neutralizing IL-1β, was shown to be associated with reduced risk of adverse cardiovascular events compared to placebo in a randomized, placebo-controlled trial. Colchicine, methotrexate, and leukotriene inhibitors also demonstrate potential for lowering cardiovascular risk through immunomodulation.

Novel lipid-modulating targets (PCSK9, ANGPTL3, CETP, apolipoprotein(a)): Key proteins in lipoprotein metabolism — including PCSK9, angiopoietin-related protein 3, cholesteryl ester transfer protein, and apolipoprotein(a) — have been identified as viable targets for intervention. Therapeutic modalities include protein inhibition, antisense oligonucleotides, small interfering RNA, and base editing approaches aimed at achieving durable reductions in ASCVD risk.

Aldosterone synthase (CYP11B2) inhibition for atrial fibrosis: Torasemide, but not furosemide, inhibits CYP11B2 activity and reduces expression of connective tissue growth factor (CTGF), lysyl oxidase (LOX), and pro-fibrotic miR-21 in cardiac fibroblasts. In a mouse model with cardiac Rac1 GTPase overexpression, long-term torasemide treatment prevented atrial fibrosis and was associated with a reduced prevalence of atrial fibrillation (33% vs. 80% in untreated animals).

Influenza vaccination as a cardiovascular preventive strategy: Multiple meta-analyses and randomized controlled trials suggest that influenza vaccination is associated with a reduced risk of major adverse cardiovascular events (MACE), particularly in high-risk individuals with preexisting cardiovascular disease, through mitigation of systemic inflammation and prevention of atherosclerotic plaque destabilization.

Hyperkalemia as a barrier to RAASi and MRA use: Renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are essential for improving outcomes in CKD and HF, yet their use is frequently limited by hyperkalemia. The pooled hyperkalemia incidence across RAASi-treated patients is 10.7%, rising to 24.4% with ACEi/ARB/ARNi + MRA combinations. While novel potassium binders (patiromer and sodium zirconium cyclosilicate) improve RAASi optimization by 38% compared with placebo and reduce potassium levels by 0.71 mEq/L, no study has demonstrated that this strategy impacts clinically important endpoints such as cardiovascular events. Additional limitations include cost, pill burden, clinical availability, and patient selection.

Safety concerns with combination therapy initiation in acute settings: Initiating sacubitril-valsartan with spironolactone during hospitalization for acute decompensated heart failure (ADHF) resulted in a significantly greater incidence of hyperkalemia (10% vs. 0%; P = .022) and a numerically higher rate of 30-day readmissions due to adverse drug reactions (6% vs. 0%; P = .079) compared with sacubitril-valsartan alone, highlighting the safety complexity of optimizing guideline-directed medical therapy in the inpatient setting.

Therapeutic inertia impeding treatment optimization: Failure to intensify therapy when targets are not met is a well-documented and pervasive problem across CVRM conditions. In the TRIUMPH trial, therapeutic inertia was more common in the fixed-dose combination (FDC) triple pill group than in the usual care group at both week 6 (86.8% vs. 63.9%; P < .001) and week 12 (90% vs. 64.8%; P < .001) among patients not at blood pressure target. In CKD and T2DM, multidisciplinary consensus confirmed that therapeutic inertia, insufficient early and intensive treatment initiation, and poor coordination between levels of care contribute substantially to persistent residual risk.

Residual cardiovascular and renal risk despite standard treatment: Patients with CKD and T2DM continue to face elevated risk of renal complications, cardiovascular events, and premature death even on current standard therapy. Multidisciplinary expert consensus identified the simultaneous implementation of three treatment pillars — renin-angiotensin system blockade, SGLT2 inhibitors, and non-steroidal MRAs — as a relevant measure to reduce this residual risk, reflecting the inadequacy of any single-agent or dual-agent approach.

Underutilization of evidence-based therapies such as SGLT2 inhibitors: Despite dapagliflozin, empagliflozin, and sotagliflozin being recommended as foundational HF therapy across the full spectrum of left ventricular ejection fraction, drug prescription rates remain substantially lower than the number of potentially eligible patients. Awareness gaps, therapeutic inertia, safety concerns, and the complexity of initiating comprehensive medical therapy simultaneously are identified barriers to their adoption in clinical practice.